154 related articles for article (PubMed ID: 38508214)
1. RPE65-Associated Retinal Dystrophies: Phenotypes and Treatment Effects with Voretigene Neparvovec.
Stingl K; Priglinger C; Herrmann P
Klin Monbl Augenheilkd; 2024 Mar; 241(3):259-265. PubMed ID: 38508214
[TBL] [Abstract][Full Text] [Related]
2. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
Kang C; Scott LJ
Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
[TBL] [Abstract][Full Text] [Related]
3. Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee.
Han J; Joo K; Kim US; Woo SJ; Lee EK; Lee JY; Park TK; Kim SJ; Byeon SH
Korean J Ophthalmol; 2023 Apr; 37(2):166-186. PubMed ID: 36950921
[TBL] [Abstract][Full Text] [Related]
4. RPE65 c.353G>A, p.(Arg118Lys): A Novel Point Mutation Associated with Retinitis Pigmentosa and Macular Atrophy.
Bjeloš M; Bušić M; Ćurić A; Šarić B; Bosnar D; Marković L; Kuzmanović Elabjer B; Rak B
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142423
[TBL] [Abstract][Full Text] [Related]
5. Pathogenicity reclassification of the
Bjeloš M; Bušić M; Ćurić A; Bosnar D; Šarić B; Marković L; Kuzmanović Elabjer B; Rak B
Ophthalmic Genet; 2023 Jun; 44(3):276-280. PubMed ID: 35904185
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
[TBL] [Abstract][Full Text] [Related]
7. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.
Med Lett Drugs Ther; 2018 Mar; 60(1543):53-55. PubMed ID: 29635265
[No Abstract] [Full Text] [Related]
8. [Gene therapy treatment based on an ophthalmic indication in hereditary retinal dystrophy caused by RPE65 biallelic gene mutation.].
Vizvári E; Smeller L; Jánossy Á; Lőrincz M; Janáky M; Tóth-Molnár E
Orv Hetil; 2022 Nov; 163(48):1923-1931. PubMed ID: 36436058
[TBL] [Abstract][Full Text] [Related]
9. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia].
Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI
Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
[TBL] [Abstract][Full Text] [Related]
11. Frequency of
Kahraman NS; Öner A; Özkul Y; Dündar M
Turk J Ophthalmol; 2022 Aug; 52(4):270-275. PubMed ID: 36017377
[TBL] [Abstract][Full Text] [Related]
12. Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.
Weng CY
Ophthalmol Retina; 2019 May; 3(5):450. PubMed ID: 31044739
[No Abstract] [Full Text] [Related]
13. Gene Therapy in Hereditary Retinal Dystrophies: The Usefulness of Diagnostic Tools in Candidate Patient Selections.
Malvasi M; Casillo L; Avogaro F; Abbouda A; Vingolo EM
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762059
[TBL] [Abstract][Full Text] [Related]
14. Properties and Therapeutic Implications of an Enigmatic D477G RPE65 Variant Associated with Autosomal Dominant Retinitis Pigmentosa.
Kiang AS; Kenna PF; Humphries MM; Ozaki E; Koenekoop RK; Campbell M; Farrar GJ; Humphries P
Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33261050
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for RPE65-related retinal disease.
Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
[TBL] [Abstract][Full Text] [Related]
16. Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy.
Lopez J; Borchert M; Lee TC; Nagiel A
Br J Ophthalmol; 2023 Mar; 107(3):299-301. PubMed ID: 35835501
[TBL] [Abstract][Full Text] [Related]
17. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec.
Kortüm FC; Kempf M; Jung R; Kohl S; Ott S; Kortuem C; Sting K; Stingl K
Acta Ophthalmol; 2022 May; 100(3):e807-e812. PubMed ID: 34289237
[TBL] [Abstract][Full Text] [Related]
18. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.
Maguire AM; Bennett J; Aleman EM; Leroy BP; Aleman TS
Mol Ther; 2021 Feb; 29(2):442-463. PubMed ID: 33278565
[TBL] [Abstract][Full Text] [Related]
19. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.
Maguire AM; Russell S; Chung DC; Yu ZF; Tillman A; Drack AV; Simonelli F; Leroy BP; Reape KZ; High KA; Bennett J
Ophthalmology; 2021 Oct; 128(10):1460-1468. PubMed ID: 33798654
[TBL] [Abstract][Full Text] [Related]
20. [Molecular exploration of the R91W (RPE65 gene) in Tunisian patients with early onset retinal dystrophy and early onset retinitis pigmentosa].
Chouchene I; Largueche L; Derouiche K; Mabrouk S; Abdelhak S; El Matri L
Tunis Med; 2015 Jul; 93(7):445-8. PubMed ID: 26757501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
